Homepage Top Section1

The deal includes joint studies combining BeOne’s cancer pipeline assets with four clinical-stage RAS(ON) inhibitors from Revolution Medicines, alongside a regional rights agreement for select Asian markets. The

Under the contract, Daiichi Sankyo will continue to handle development, manufacturing, and supply of the therapy while Innovent Biologics will lead market promotion and commercialisation activities in China.

The agreement involves access to ALT-B4 (berahyaluronidase alfa), a recombinant human hyaluronidase created with Alteogen’s Hybrozyme platform. This technology is intended to convert biologics typically given via intravenous

The funds will be used for AsymBio’s principal business operations and drive further expansion of its manufacturing capacity. Asymchem Group will contribute 1.05bn yuan while Hillhouse Qirui will

The company said existing investors Duquesne Family Office and Bristol Myers Squibb participated in the round, joined by new investors Catalio Capital Management, Eli Lilly and Company, and

Repatha is intended for adults with established or high risk of atherosclerotic cardiovascular disease (ASCVD) and aims to reduce the risk by decreasing low-density lipoprotein cholesterol (LDL-C) levels,

Lu AH69593 is an oral, small-molecule agonist of the orexin 2 receptor (OX2R). The compound is currently being studied in a Phase Ib clinical trial focused on patients

The gene therapy is under investigation in adults living with BAG3 DCM, a genetic condition that leads to progressive heart failure and reduced survival despite existing treatments. AFTX-201

PPL-001 is a gene-corrected haematopoietic stem and progenitor cell (HSPC) therapy. Under the collaboration, Cellares will adapt the PPL-001 manufacturing process for its Cell Shuttle platform, and support